Identification of an autocrine negative growth factor: Mouse β-galactoside-binding protein is a cytostatic factor and cell growth regulator

doi:10.1016/0092-8674(91)90211-G

Cell

Volume 64, Issue 1, 11 January 1991, Pages 91-97

https://doi.org/10.1016/0092-8674(91)90211-G Get rights and content

Abstract

Murine β-galactoside-binding protein, a protein classified as a soluble lectin, is shown to be a cell growth-regulatory molecule and a cytoatatic factor. The growth-inhibitory effect is not related to lectin properties, and competition assays indicate that the protein binds to specific cell surface receptors with high affinity. It exerts control in G0 and at G2, both as a regulator of cell replication and as a cytostatic factor.

References (38)

R.F. Cerra et al.
Three soluble rat β-galactoside binding lectins
J. Biol. Chem.
(1985)
P.O. Couraud et al.
Molecular cloning, characterisation and expression of a human 14-kDa lectin
J. Biol. Chem.
(1989)
A. de Waard et al.
Isolation and properties of β-galactoside binding lectins of calf heart and lung
J. Biol. Chem.
(1976)
J. Massagué
The transforming growth factors
Trends Biochem. Sci.
(1985)
J. Monod et al.
On the nature of allosteric transition: a plausible model
J. Mol. Biol.
(1965)
Y. Ohyama et al.
Nucleotide sequence of chick 14K β-galactoside-binding lectin mRNA
Biochem. Biophys. Res. Commun.
(1986)
V. Wells et al.
Expression of the 2-5A system during the cell cycle
Exp. Cell Res.
(1985)
W.M. Abbott et al.
Evidence that the 14kDa soluble β-galactoside-binding lectin in man is coded by a single gene
Biochem. J.
(1989)
S.H. Barondes
Soluble lectins: a new class of extracellular proteins
Science
(1984)
H.P.J. Bennett et al.
The use of perfluorinated carboxylic acid in the reversed phase HPLC of peptides
J. Liquid Chromat.
(1980)

F.D. Bohmer et al.

Identification of a polypeptide growth inhibitor from bovine mammary gland

J. Biol. Chem.

(1987)

R.A. Childs et al.

β-Galactoside-binding muscle lectins of man and monkey show antigenic cross-reactions with those of bovine origin

Biochem. J.

(1979)

L.B. Clerch et al.

Sequence of a full-length cDNA for rat lung β-galactoside-binding protein: primary and secondary structure of the lectin

Biochemistry

(1988)

A.A. Creasey et al.

Growth regulation of melanoma cells by interferon and (2′–5′) oligo-adenylate synthetase

Mol. Cell. Biol.

(1983)

C.A. Frocklick et al.

Purification and initial characterization of a type β transforming growth factor from human placenta

M.A. Gitt et al.

Evidence that a human soluble β-galactoside-binding lectin is encoded by a family of genes

M. Hunkapiller

Applied Biosystems Protein Sequencer User Bulletin

(1985)

M. Kozak

Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes

Cell

(1986)

S.L. Lin et al.

Interferon inhibits the establishment of competence in G0/S-phase transition

Science

(1986)

Cited by (250)

Primary Human Colonic Mucosal Barrier Crosstalk with Super Oxygen-Sensitive Faecalibacterium prausnitzii in Continuous Culture
2021, Med
The gut microbiome plays an important role in human health and disease. Gnotobiotic animal and in vitro cell-based models provide some informative insights into mechanistic crosstalk. However, there is no existing system for a long-term co-culture of a human colonic mucosal barrier with super oxygen-sensitive commensal microbes, hindering the study of human-microbe interactions in a controlled manner.
Here, we investigate the effects of an abundant super oxygen-sensitive commensal anaerobe, Faecalibacterium prausnitzii, on a primary human mucosal barrier using a gut microbiome (GuMI) physiome platform that we designed and fabricated.
Long-term continuous co-culture of F. prausnitzii for 2 days with colon epithelia, enabled by continuous flow of completely anoxic apical media and aerobic basal media, results in a strictly anaerobic apical environment fostering the growth of and butyrate production by F. prausnitzii, while maintaining a stable colon epithelial barrier. We identify elevated differentiation and hypoxia-responsive genes and pathways in the platform compared with conventional aerobic static culture of the colon epithelia, attributable to a combination of anaerobic environment and continuous medium replenishment. Furthermore, we demonstrate the anti-inflammatory effects of F. prausnitzii through histone deacetylase (HDAC) and the Toll-like receptor-TLR-nuclear factor κB (NF-κB) axis. Finally, we identify that butyrate largely contributes to the anti-inflammatory effects by downregulating TLR3 and TLR4.
Our results are consistent with some clinical observations regarding F. prausnitzii, thus motivating further studies using this platform with more complex engineered colon tissues for understanding the interaction between the human colonic mucosal barrier and microbiota, pathogens, or engineered bacteria.
US National Institute of Biomedical Imaging and Bioengineering, Boehringer Ingelheim Strategic Hub for Innovative New Therapeutics Concept Exploration (SHINE) Program, US National Institute of Environmental Health Sciences.
Antimicrobial response of galectin-1 from rock bream Oplegnathus fasciatus: Molecular, transcriptional, and biological characterization
2016, Fish and Shellfish Immunology
In this study, we describe the identification and characterization of a proto type galectin, galectin-1, from rock bream Oplegnathus fasciatus (OfGal-1). Galectins are evolutionarily conserved carbohydrate binding lectins that show a wide range of functions related to development and immune physiology. They have been identified as pattern recognition receptors of innate immune system that recognize a broad range of microbes. OfGal-1 cDNA comprised of 993 bp with an open reading frame of 408 bp that encodes 135 amino acids. A single carbohydrate recognition domain was present in the OfGal-1 amino acid sequence. The sequence comparison by multiple and pairwise alignments and the phylogenetic tree emphasized the strong evolutionary conservation of Gal-1. The typical β-sandwich structure was identified from the predicted tertiary structure. The constitutive expression of mRNA transcripts was detected in a wide range of tissues examined, with the highest expression in the heart. Immune challenges with live bacteria (Edwardsiella tarda and Streptococcus iniae), rock bream irido virus, and mitogens (lipopolysaccharide and poly I:C) modulated the expression of OfGal-1 mRNAs in the gills, head kidney, and liver. The recombinant OfGal-1 (rOfGal-1) strongly agglutinatinated the human erythrocytes, and this hemagglutination was inhibited by lactose and d-galactose. A wide range of bacteria (S. iniae, S. parauberis, Escherichia coli, Edwardsiella tarda, Vibrio anguillarum, Vibrio harveyi, and Vibrio tapetis) and a ciliate (Miamiensis avidus) were also effectively recognized by rOfGal-1. Significant antiviral activity against rock bream irido virus was also demonstrated by rOfGal-1. Collectively, results from the present study indicate that OfGal-1 can recognize a wide range of microbes and is a vital pattern recognition receptor in the innate immune system of rock bream.
Induction of galectin-1 by TGF-β1 accelerates fibrosis through enhancing nuclear retention of Smad2
2014, Experimental Cell Research
Citation Excerpt :
The lectin activity of Gal-1 generally acts in the extracellular milieu, whereas its signaling functions, which affect immune responses and cell growth activity, typically occur in the intracellular space. Gal-1 has been associated with a variety of cell functions, including proliferation, migration, adhesion, immune responses, apoptosis, inflammation, and carcinogenesis [9–13]. Studies have shown that recombinant Gal-1 ameliorates nephrotoxic serum nephritis in rats, and suppresses type I collagen transcription in TGF-β1-stimulated renal tubular epithelial cells, suggesting that it may play a protective role in glomerulonephritis and renal fibrosis [14,15].
Fibrosis is one of the most serious side effects in cancer patients undergoing radio-/ chemo-therapy, especially of the lung, pancreas or kidney. Based on our previous finding that galectin-1 (Gal-1) was significantly increased during radiation-induced lung fibrosis in areas of pulmonary fibrosis, we herein clarified the roles and action mechanisms of Gal-1 during fibrosis. Our results revealed that treatment with TGF-β1 induced the differentiation of fibroblast cell lines (NIH3T3 and IMR-90) to myofibroblasts, as evidenced by increased expression of the fibrotic markers smooth muscle actin-alpha (α-SMA), fibronectin, and collagen (Col-1). We also observed marked and time-dependent increases in the expression level and nuclear accumulation of Gal-1. The TGF-β1-induced increases in Gal-1, α-SMA and Col-1 were decreased by inhibitors of PI3-kinase and p38 MAPK, but not ERK. Gal-1 knockdown using shRNA decreased the phosphorylation and nuclear retention of Smad2, preventing the differentiation of fibroblasts. Gal-1 interacted with Smad2 and phosphorylated Smad2, which may accelerate fibrotic processes. In addition, up-regulation of Gal-1 expression was demonstrated in a bleomycin (BLM)-induced mouse model of lung fibrosis in vivo. Together, our results indicate that Gal-1 may promote the TGF-β1-induced differentiation of fibroblasts by sustaining nuclear localization of Smad2, and could be a potential target for the treatment of pulmonary fibrotic diseases.
The end of KRAS, and other, cancers? A new way forward
2014, Drug Discovery Today
Mutant KRAS, as well as other mutant driver genes and epidriver genes, is a dominant determinant of resistance to cancer therapeutics. The recent introduction of targeting therapies based on drugs that inhibit the kinase catalytic function of nodal points along the Ras/extracellular-signal-regulated kinase (ERK) and the phosphatidylinositol-3-kinase (PI3K)/Akt cascades is meeting with limited success. Against this background, recent evidence shows that the β-galactoside-binding protein (βGBP) molecule, a physiological PI3K inhibitor, is a potent inducer of apoptosis in KRAS-mutant cancer cells (along with other aggressive cancer cells of different genetic makeup) and that it is therapeutically effective in vivo. Absence of p53 or phosphatase and tensin homolog (PTEN) tumor suppressor function or added activating PI3K mutations does not affect βGBP function. In contrast to the concept of one drug against one target, βGBP operates through alternative physiological routes.
Unraveling galectin-1 as a novel therapeutic target for cancer
2014, Cancer Treatment Reviews
Galectins belong to a family of carbohydrate-binding proteins with an affinity for β-galactosides. Galectin-1 is differentially expressed by various normal and pathologic tissues and displays a wide range of biological activities. In oncology, galectin-1 plays a pivotal role in tumor growth and in the multistep process of invasion, angiogenesis, and metastasis. Evidence indicates that galectin-1 exerts a variety of functions at different steps of tumor progression. Moreover, it has been demonstrated that galectin-1 cellular localization and galectin-1 binding partners depend on tumor localization and stage. Recently, galectin-1 overexpression has been extensively documented in several tumor types and/or in the stroma of cancer cells. Its expression is thought to reflect tumor aggressiveness in several tumor types. Galectin-1 has been identified as a promising drug target using synthetic and natural inhibitors. Preclinical data suggest that galectin-1 inhibition may lead to direct antiproliferative effects in cancer cells as well as antiangiogenic effects in tumors. We provide an up-to-date overview of available data on the role of galectin-1 in different molecular and biochemical pathways involved in human malignancies. One of the major challenges faced in targeting galectin-1 is the translation of current knowledge into the design and development of effective galectin-1 inhibitors in cancer therapy.
Analysis of homodimeric avian and human galectins by two methods based on fluorescence spectroscopy: Different structural alterations upon oxidation and ligand binding
2012, Biochimie
Spectroscopic monitoring is applied to detect structural alterations for homodimeric adhesion/growth-regulatory galectins. Mammalian galectin-1 and the avian ortholog CG-1B, due to their distinct patterns of cysteine positioning, can undergo oxidation. When monitoring tryptophan fluorescence anisotropy comparatively, an indicator of structural changes affecting rotational diffusion, segmental motion and/or fluorescence life time, reductions are seen in both cases upon oxidation. The decrease was especially marked for the human protein, more than 2-fold compared to the avian lectin. Using this approach to analyze binding of lactose, equilibrium and kinetic binding constants of both proteins were similar. This result is corroborated by fluorescence correlation spectroscopy with labeled proteins. Of note, the diffusion constant of CG-1B increased by 5.6% in the presence of lactose, as has been seen for the human protein. When processing the other two homodimeric avian galectins (CG-1A, CG-2) accordingly it was revealed that sequence homology does not translate into identical behavior. The diffusion constant of CG-1A was not affected, a slight decrease (−3.8%) was observed for CG-2. Obviously, alterations induced by oxidation and responses to ligand binding are different between these closely related proteins. Methodologically, the two spectroscopic techniques are proven to be sensitive and robust sensors for detecting intergalectin differences.

View all citing articles on Scopus

View full text

Cell

ArticleIdentification of an autocrine negative growth factor: Mouse β-galactoside-binding protein is a cytostatic factor and cell growth regulator

Abstract

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Trends Biochem. Sci.

J. Mol. Biol.

Biochem. Biophys. Res. Commun.

Exp. Cell Res.

Evidence that the 14kDa soluble β-galactoside-binding lectin in man is coded by a single gene

Biochem. J.

Soluble lectins: a new class of extracellular proteins

Science

The use of perfluorinated carboxylic acid in the reversed phase HPLC of peptides

J. Liquid Chromat.

Identification of a polypeptide growth inhibitor from bovine mammary gland

J. Biol. Chem.

β-Galactoside-binding muscle lectins of man and monkey show antigenic cross-reactions with those of bovine origin

Biochem. J.

Sequence of a full-length cDNA for rat lung β-galactoside-binding protein: primary and secondary structure of the lectin

Biochemistry

Growth regulation of melanoma cells by interferon and (2′–5′) oligo-adenylate synthetase

Mol. Cell. Biol.

Purification and initial characterization of a type β transforming growth factor from human placenta

Evidence that a human soluble β-galactoside-binding lectin is encoded by a family of genes

Applied Biosystems Protein Sequencer User Bulletin

Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes

Cell

Interferon inhibits the establishment of competence in G0/S-phase transition

Science

Article
Identification of an autocrine negative growth factor: Mouse β-galactoside-binding protein is a cytostatic factor and cell growth regulator